Loading
Phone :
+1 (858) 366 - 8608
Address :
NovaRhythm Biosciences, Inc
9311 SE Maricamp Rd #1007
Ocala, FL 34472 USA
Email :
info@novarhythmbio.com

Corporate Strategy

Program Status

From Late-Stage Preclinical to First-in-Human

SAR-297871 enters NovaRhythm’s portfolio as a late-stage preclinical asset supported by extensive prior data packages from Sanofi, including medicinal chemistry, pharmacology, toxicology, and human tissue studies. NovaRhythm’s development plan focuses on efficient de-risking and rapid translation to human proof-of-mechanism.

DEVELOPMENT ROADMAP
(IND → PHASE 1)

Step 1 – IND-Enabling Activities

  • – CMC (Chemistry, Manufacturing & Controls)
  • – Final preclinical safety and toxicology work
  • – Regulatory engagement and IND preparation

Step 2 – IND Submission

  • – Submission of Investigational New Drug (IND) application
  • – Regulatory review and clearance to proceed with clinical trials

Step 3 – Phase 1 Clinical Trial

  • – Single and multiple ascending dose study in healthy volunteers (or relevant population, as finalized with regulators)
  • – Primary endpoints: safety, tolerability, pharmacokinetics
  • – Secondary / exploratory:  pharmacodynamic signals, early cardiac biomarker assessment

Step 4 – Phase 2 Readiness & Strategic Options

With Phase 1 safety and PK established, NovaRhythm plans to:

  • – Design focused Phase 2 trials in AF patients to evaluate efficacy and dose optimization
  • – Drive strategic partnering or transaction opportunities with larger cardiovascular or pharma partners interested in AF innovation